Knowledge HQ

This protocol describes the isolation and feeder-cell-based expansion of NK cells. To demonstrate clinical scalability, the method was tested on GMP-grade G-Rex 100M platforms, achieving clinically relevant numbers of highly pure and functional NK cells suitable for adoptive therapy.

This paper details the GMP manufacturing of CISH KO TILs for GI cancers. Tumor fragments were outgrown in 24-well G-Rex plates, and selected TILs were expanded in 100 cm² G-Rex vessels. An automated liquid handling system was developed to perform media exchanges directly in the G-Rex 24 plates.

The authors developed a GMP-feasible protocol for expanding TILs from sarcoma without anti-CD137 agonist, using CD3/CD28 beads instead. The rapid expansion phase (REP) utilized G-Rex 10M, which achieved a 2- to 3-fold higher expansion compared to T-75 flasks, boosting clinical feasibility.

This study demonstrates a semi-automated workflow for non-viral CAR T-cell production using digitally connected instruments. T cells were isolated, activated, and then cultured in G-Rex 100 and G-Rex 100M. The process yielded high-quality CAR T cells with reduced manual touchpoints and variability.

This paper describes the engineering of allogeneic CD19 CAR T cells with FKBP12 knockout to resist mTOR inhibitors like tacrolimus and rapamycin. The study utilized 24-well G-Rex plates for the recovery and expansion of nucleofected T cells. These cells demonstrated deep B-cell depletion in immunosuppressed mice.

This study presents a GMP-compliant process for manufacturing off-the-shelf NK cells from CD34+ HSPCs. The protocol was adapted to G-Rex 10M and 100M to facilitate scaling and reduce handling. The resulting NK cells showed high recovery, viability, and potent anti-tumor activity in vivo and in vitro.

This poster explores using cryopreserved G-CSF-mobilized apheresis units for manufacturing CIK and CAR-CIK cells. It compares manual versus automated washing and expansion methods. The use of G-Rex allowed for higher cell expansion in significantly less time (9-12 days) compared to standard.

This review addresses challenges in scaling iPSC-derived therapies, emphasizing automation, closed systems, and Quality-by-Design. It evaluates various technologies for expansion and differentiation. 1L and 5L G-Rex are referenced as technologies used for expansion during research and early process development.

This study establishes a GMP-compliant protocol for expanding thymus-derived regulatory T cells (Thy-Tregs). By optimizing CD8 depletion, CD25 enrichment, and cytokine stimulation, the authors achieved high purity. G-Rex (G-Rex 10 and 100) were successfully used to scale up production for clinical trials.

This study analyzes adaptive immune responses in PSC. Cells were pulsed with peptides in a 24-well G-Rex device to generate EBV-specific T cell lines.

RAPA-201 T cells, reprogrammed via mTOR inhibition, showed safety and efficacy in RRMM patients. The manufacturing process involved incubating cells in G-REX culture vessels with cytokines and rapamycin.

The authors demonstrate that DNA-PK inhibitors enhance CRISPR/Cas9 KI efficiency. Under GMP-optimized conditions, T cells were cultured in G-Rex-100M vessels and seeded in G-Rex 24 well plates after electroporation.